T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy is a research paper published in Journal for ImmunoTherapy of Cancer (2025). On theSindex it has a DataRank of 0.510. It has been cited 16 times, with 16 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0.0849
From 9 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 16 citers.
National Cancer Institute
Grant: P30 CA016059
MSD Sharp and Dohme
Grant: N/A
National Institutes of Health
Grant: 4P30CA016059-35
Massey Cancer Center Support Grant
Fields of Study
MeSH Terms
Keywords